Charles River Laboratories International, Inc. closed at $353.11 on November 10, 2026, a gain of 4.71% in the latest 24-hour session. The move extended a broader upswing that has carried the stock higher in recent weeks.
Over the past seven days, CRL shares have risen 4.33%, while the 30-day gain stands at 17.01%, reflecting sustained buying interest in the contract research organization. The company's market capitalization reached $16.17 billion as of the close.
The 30-day advance of 17.01% represents one of the more notable stretches of appreciation for the stock in recent memory, though the pace of near-term gains moderated slightly on a week-over-week basis compared with the broader monthly move.
Charles River Laboratories provides drug discovery and development services to pharmaceutical and biotechnology clients. The shares' performance over the measured periods places CRL among the stronger performers tracked in the sector over the trailing month.
